Medicinal, nutritional, and nutraceutical potential of *Sparassis crispa s. lat.*: a review

Neha Sharma¹, Ashwani Tapwal¹*, Rachna Verma²*, Dinesh Kumar³, Eugenie Nepovimova⁴ and Kamil Kuca⁴*

**Abstract**

*Sparassis crispa* is an edible mushroom exhibiting a wide range of medicinal properties. It is recognized for therapeutic value because of the high β-glucan content in the basidiomes. The broad range of its reported curative effects include anti-tumour, anti-cancer, immune-enhancing, hematopoietic, anti-angiogenic, anti-inflammatory, anti-diabetic, wound-healing, antioxidant, anti-coagulant, and anti-hypertensive properties. However, most of the studies are conducted on immunomodulatory and anticancer activities. Besides this, it also exhibits anti-microbial properties due to the presence of sparassol. Technology is now available for the cultivation of *S. crispa* on coniferous sawdust. This review is an attempt to focus on its distribution, taxonomy, chemical composition, medicinal properties, potential applications, and artificial cultivation.

**Keywords:** Anti-cancer, Artificial cultivation, β-glucan, Cauliflower mushroom, Immunomodulatory, Sparassol

**INTRODUCTION**

Medicinal mushrooms are macroscopic fungi used in the mitigation, prevention, and curing of diseases. Mushrooms are a rich source of proteins, essential amino acids, vitamins, and minerals; and have a wide spectrum of uses as food and medicine. They can be used in the form of extracts or directly included in the diet. Mushrooms have been used in medicine since ancient times and this potential has led to them gaining popularity in current times. Medicinal properties can be attributed to the low-fat content, with a high proportion of unsaturated fatty acids along with high fibre content, triterpenes, phenolic compounds, sterols, eritadenine, and chitosan. Glucans (β-1,3-glucans), triterpenoids, and ergosterol are key active compounds. Mushrooms have also gained importance in medicine as they contain vital components which provide nutrition and health benefits for humans (Ogidi et al. 2020).

*Sparassis crispa*, commonly known as cauliflower mushroom after the shape of the above ground basidiomes which resembles a cauliflower. An edible mushroom with a variety of medicinal properties, it is widely distributed all over the north temperate zone and grows as a saprophyte or parasite on the stumps of conifers and some hardwoods, especially oaks causing a brown rot, and the basidiomes are generally seen on or near the base of a tree trunk. The species is well known for its medicinal significance arising from a variety of pharmacologically

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
active substances and incorporated into health supplements. It is traditionally used in Chinese medicine. Medicinal properties are primarily due to a high β-glucan (sparan) content which can constitute more than 40% of the dry weight of the mushroom (Ohno et al. 2000).

It is reported as exhibiting antimicrobial, anti-angiogenic, immunity enhancing, wound-healing, hematopoietic, anti-inflammatory, and antioxidant activities (Harada et al. 2002a; Harada et al. 2006; Tada et al. 2007; Yamamoto et al. 2009; Kwon et al. 2009). Besides this, it also contains sparassol (methyl-2-hydroxy-4-methoxy-6-methylbenzoate), which has antibacterial and antifungal properties. Sparassis crispa has a distinctive aromatic scent that can be attributed to 3-octanone, DL-3-octanol, and 1-octen-3-ol (Shin et al. 2007). It also has the potential to be used in the food industry as it contains hydrocolloid (Hao et al. 2018; Vaka et al. 2020). Artificial cultivation of S. crispa is practiced in many parts of the world.

**TAXONOMY AND MORPHOLOGY**

The generic name Sparassis is derived from a Greek word meaning ‘to tear’, because the fronds appear as if they are torn. The genus was first described in 1821 by the Swedish mycologist Elias Fries, and includes species that have an amphigenous hymenium and give rise to flabella from a central mass (Wang et al. 2004). The specific epithet crispa recalls the finely curled lobes of the basidiome, which are quite pliable and cartilaginous in texture. Index fungorum (http://www.indexfungorum.org/) lists 17 species names under this genus, but molecular phylogenies have reduced the number to ten (Zhao et al. 2013). The genus belongs to the Sparassidaceae (Polyporales, Agaricomycetes). It was earlier described as Elvela ramosa (Schaeffer, 1772) then Wulfen (1781) described it as Clavaria crispa and it was subsequently transferred to Sparassis by Fries (1821, Burdassal & Miller 1988). More recent insights into the taxonomy of genus Sparassasis relating taxa to geographical distribution is provided by Dai et al. (2006) and Ryoo et al. (2013). Early research on S. crispa from Asian countries appears to reflect the S. crispa s. lat. monophyletic clade, but based on morphological and molecular studies material named as S. crispa from Asia is different to that from Europe and North America. The predominant Asian isolate was therefore named S. latifolia, based on morphological characters and molecular sequence analysis of the rDNA, particularly the internal transcribed spacer (ITS) region (Ryoo et al. 2013).

In the present review, because of this issue, the name “S. crispa” refers to the species in the broad circumscription unless otherwise indicated.

It is important that the identification of fungal species used in experimental and other studies is authenticated using molecular methods, and that representative material be deposited in a public fungarium or culture collection so that it is available to check the identities of the fungi as well as for future research. The metadata linked with specimens in fungaria and culture collection is now becoming more publicly available as a result of large-scale digitization. Taxonomy, sampling location, collection date, and habitat/substrate information, as well as DNA sequences and biochemical properties, can all now be used to their maximum potential (Andrew et al. 2018).

**Anatomical features**

*Basidiome* large, rounded and branched with leaf-like projections called flabella; flabella densely grouped, flat, waxy, undulating, fleshy, emerging from a branched central base, whitish to cream in color, becoming darker with age; hymenium amphigenous, surface smooth (Fig. A). *Hyphe*ae septate, thin-walled, monomitic, branched, hyaline, 4–6 µm wide, clamp connections present. *Basidia* club-shaped, sterigmata 4, 2–5 µm tall. *Basidiospores* smooth, thin-walled, ovoid, hyaline, with a central guttule, 6.0–7.5 × 4.0–5.0 µm, non-amyloid (Fig. B). *Spore print* white to cream (Rana 2007).

**Culture characteristics**

Slow growing, colony is circular, cottony, initially white, later on, turn pale on ventral side, form dense and sparse zones of concentric rings, margins smooth. It grows to a diameter of 75 mm on PDA medium, after 15 days of incubation at 25 °C (Fig. 1c).

**GENOME SEQUENCE AND PHYLOGENY OF SPARASSIS CRISPA**

According to Kiyama et al. (2018), S. crispa has a 39.0 Mb genome, encoding 13,157 genes. Phylogenetic analysis suggests that about 94 Mya it diverged from *Postia placenta*, a resupinate brown-rot fungus. Bashir et al. (2020) reported a complete mitochondrial genome sequence of S. crispa, including 139,253 base pairs with 26.47% Guanine-Cytosine and 73.53% Adenine-Thymine content. It contains 47 genes which include 27 tRNA, 5 ribosomal RNA genes and 15 protein-coding genes. The phylogenetic analysis on *atp6* sequence revealed a close relationship with *S. radicata* (Dai 2006).

**ECOLOGY AND DISTRIBUTION**

*Sparassis crispa* is considered a biotroph, weak parasite, and saprotroph in nature (Julich 1984). It invades the roots of conifers and some hardwood tree species causing
brown heart rot. The fungus thrives in forests having fine soil and high moisture (Park et al. 2009). *Sparassis crispa* basidiomes can be spotted during July to October at or near the base of host trees. *S. crispa s. lat.* is found in the USA, Australia (Martin & Gilbert 1976), France, Germany, Russia (Dyakov et al. 2011), China, Japan, Tibet, Nepal (Devkota 2009), Belarus, Turkey (Kalyoncu et al. 2010) and India (Lakhanpal 2014). In India, it is most commonly found in Himachal Pradesh (Chauhan et al. 2014), Uttarakhand (Kumar et al. 2017), Jammu-Kashmir (Lalotra et al. 2018) and Maharashtra (Fulzele 2013).

**PATHOGENICITY AND HOST RANGE**

*Sparassis crispa* does not cause major harm to trees, and infected trees can live for many years supporting newly grown mushrooms annually. It is a weak parasite and has little ability to invade the living tissues of host plants (Woodward et al. 1993). It is generally found on physiologically weakened or recently killed trees, logs, and thick fallen branches. The fungus mostly colonizes the living trees through roots and causes brown cubical rot of root and stem. The rot progresses from the root to the heartwood and gradually invades the lower part of the tree (Karadžić, 2006). The presence of wounds on the trunk and roots facilitates the entry of the pathogen (Park et al. 2009). Oh et al. (2009) surveyed the natural habitat of *S. crispa* for investigating ecological conditions. *S. crispa* was found on *Larix kaempferi* and *Pinus koraiensis* tree species growing in relatively fertile forest soils and especially slightly acidic soils. *Pinus nigra* and *Pinus sylvestris* are especially susceptible to this fungus (Radulovic et al. 2019). Few common hosts of *S. crispa* reported by different researchers are listed in Table 1.

**ETHNOMYCOLOGY**

*Sparassis crispa* is considered edible all over the world. It is usually consumed in a young fresh condition, but sometimes the mushrooms are dried and preserved for future use. It has been used in China, Japan, and Korea in traditional culinary practices for centuries. In India, it is reported as edible from Jaunsar, Uttarakhand (Kumar et al. 2017); Kinnaur, Himachal Pradesh (Chauhan et al. 2014), and Jammu-Kashmir (Lalotra et al. 2018; Aryal & Budhathoki 2013).

### Table 1

| Host tree | References |
|-----------|------------|
| Abies holophylla | Ryu et al. (2009) |
| Cedrus deodara | Semwal et al. (2014) |
| Ceiba pentandra | Kamble et al. (2012) |
| Larix deciduas | Woodward et al. (1993) |
| Larix kaempferi | Ryu et al. (2009); Oh et al. (2009) |
| Melia azedarachta | Nasim et al. (2007) |
| Picea sp. | Wang et al. (2004) |
| Pinus brutia | Kalyoncu et al. (2010) |
| Pinus densiflora | Ryu et al. (2009); Farooq et al. (2014) |
| Pinus koraiensis | Dai et al. (2007); Ryu et al. (2009); Oh et al. (2009) |
| Pinus nigra | Martin and Gilbertson (1976) |
| Pinus sylvestris | Burdsall and Miller (1988) |
| Pinus virginiana | Martin and Gilbertson (1976) |
| Pseudotsuga menziesii | Von-Siepmann (1976) |
| Quercus alba | Martin and Gilbertson (1976) |
| Quercus lamellose | Devkota (2009) |
| Quercus semecarpifolia | Devkota (2009) |
| Tectona grandis | Aryal and Budhathoki (2013) |
| Tsuga Dumosa | Devkota (2009) |
CHEMICAL CONSTITUENTS

*Sparassis crispa* basidiomes are primarily composed of proteins, lipids, carbohydrates, and minerals. The major part is of carbohydrates, which have the highest content of β-glucan. It is estimated that more than 40% of the dried basidiomes are composed of β-glucan (Ohno 2000). More than 30 compounds have been isolated from *S. crispa*, including polyphenols, flavonoids, terpenoids (Kodani et al. 2009), vitamins, steroids (Lee et al. 2016c), alkaloids, phthaloids (Yoshikawa et al. 2010), and some others (Kawagishi et al. 2007). Shin et al. (2007) analyzed the minerals, amino acids, and vitamin content of the *S. crispa* basidiomes and found that the mushroom possessed a high amount of potassium (K) and appreciable amounts of phosphorus (P) and sodium (Na). Among the amino acids, glutamine was present in the highest amount followed by asparagine. The mushroom also contains a high amount of vitamin E and vitamin C.

Indole, tryptamine, melatonin, gentisic acid, gallic acid, p-hydroxybenzoic acid, o-cumaric acid, caffeic acid, protocatechuic acid, syringic acid, and ergosterol are all antioxidant compounds reported from *S. crispa*. Among these, p-Hydroxybenzoic acid was recorded to be the most abundant with 43.92 mg per 100 g dry weight of the mushroom.

Indole, tryptamine, melatonin, gentisic acid, gallic acid, p-hydroxybenzoic acid, o-cumaric acid, caffeic acid, protocatechuic acid, syringic acid, and ergosterol are all antioxidant compounds reported from *S. crispa*. Among these, p-Hydroxybenzoic acid was recorded to be the most abundant with 43.92 mg per 100 g dry weight of the basidiome (Kawagishi et al. 2007).

Kavisheere et al. (2008) investigated the fatty acids of *S. crispa* and some other Indian edible mushrooms and, recorded a high content of essential fatty acids in this mushroom. Hayashi et al. (2008) reported two chalcones, xanthoangelol and 4-hydroxyderricin, from *S. crispa*. Yoshikawa et al. (2010) isolated phthalid compounds; ubiquinone-9, hanabiratakelide A, hanabiratakelide B, hanabiratakelide C, and two unsaturated compounds. Other than these compounds, sparalide A, methyl 2,4-dihydroxy-3-methoxy-6-methylbenzoate, and 50-deoxy-50-methylthiodenosine, were isolated from *S. crispa* by Bang et al. (2018). Chandrasekaran et al. (2011) found an alkaliphilic esterase from the basidiomes of *S. crispa* which shows high specificity towards moderate thermostability, short-chain esters, and alkaliphilic properties; it consequently has potential as a biocatalyst in the pharmaceuticals, food, and chemical industries. Choi et al. (2016) isolated a fibrinolytic enzyme wulfase, and Nowacka-Jechalke et al. (2021) observed a dominant presence of carbohydrates while other components were seen in traces.

Horie et al. (2008) carried out a proteomics analysis of *S. crispa* using one and two dimensional gel electrophoresis-based complementary proteomics approaches. Using 1-DGE and 2-DGE in combination with liquid chromatography, Mass spectroscopy, and N-terminal amino acid sequencing, 115 proteins were identified from the mushroom.

MEDICINAL PROPERTIES

Several authors have summarized the pharmacological potential of *S. crispa* viz. anti-tumour (Ohno et al. 2000, 2002; Yamamoto et al. 2007), anti-cancer (Ohno et al. 2003; Yamamoto et al. 2009; Yoshikawa et al. 2010), immune-enhancing (Hasegawa et al. 2004; Kim et al. 2010) hematopoietic (Harada et al. 2006; Harada et al. 2002a, b), anti-angiogenic (Yamamoto et al. 2009), anti-inflammatory (Yao et al. 2008; Kim et al. 2012; Wang et al. 2019; Han et al. 2019), anti-diabetic (Yamamoto & Kimura 2010), wound-healing (Kwon et al. 2009; Wang et al. 2019) antioxidant (Kim et al. 2008; Joshi & Sagar 2014; Lee et al. 2016a, b, c), anticoagulant (Choi et al. 2016) and anthy hypertensive (Yoshitomi et al. 2011). The bioactivities of *S. crispa* are mainly attributed to the presence of a high amount of β-glucan. "Phytochemicals" from the mushroom *S. crispa* were also observed to inhibit LPS-stimulated cytokine production in bone marrow-derived dendritic cell (Bang and Lee 2019). Nowacka-Jechalke et al. (2021) confirmed that crude polysaccharide extracts from *S. crispa* possess many biological activities including anticancer, anti-inflammatory, and antioxidant properties. The different medicinal properties associated with particular chemical constituents of *S. crispa* are summarized in Table 2.

Anti-cancer activity

The important immunomodulator 6-branched 1,3-β-D glucan exists as an active compound in *S. crispa*, and exhibits anticancer activity by modulating the immune response (Ohno et al. 2000). The major side-effect reported from most of the anti-cancer chemotherapeutic drugs is neutropenia and impairment of blood-forming functions. The β-glucan is known to enhance the hematopoietic response and therefore has potential application in cancer treatment (Harada 2006).

Ohno et al. (2000) recorded antitumor activity against a solid form of sarcoma in ICR mice (a strain of albino mice originated in SWISS and selected to create a fertile mouse line) by polysaccharide fractions of 1,3 β-glucan extracted from *S. crispa*. According to Ohno et al. (2002), oral administration of the β-glucan fraction CA1 (extracted with cold NaOH), enhanced the anticancer activity by influencing the hematopoietic response in leukopenic mice (after cyclophosphamide induction), thereby increasing white blood cell count. *In vitro* investigation of CY (cyclophosphamide) treated spleen cell culture recorded higher production of interleukin-6 and interferon-γ, on treatment with CA1. The enhancement in hematopoietic response can be attributed to increased cytokine production. Harada et al. (2002a, b) also reported enhancement of the hematopoietic response in CY (Cyclophosphamide) induced...
leukopenic mice by intraperitoneal administration of SCG (a purified beta-glucan preparation). The recovery rate of monocytes and granulocytes in the spleen, liver, peritoneal cavity, and bone marrow (BM) was higher than control. The concentration of natural killer cells and γδ T cells in the spleen, liver, and peritoneal cavity was also increased. They opined that IL-6 might be the key cytokine for the enhanced hematopoietic response by SCG because its production was more in SCG treated CY mice. On administration of SCG, splenocytes from naive DBA/1 (an inbred strain of mice susceptible to arthritis) and DBA/2 mice (another inbred strain) were reported to have reacted with it and produced interferon-γ (IFN-γ) (Harada et al. 2002b). Ohno et al. (2000) examined the cytokine-inducing capacity of SCG in healthy human volunteers and recorded increased cytokine synthesis of whole blood cell culture in dose-dependent manner. Complement system component (C5a), was released by SCG in a dose dependent manner. In a clinical trial, oral administration of powdered S. crispa (300 mg/day) to several cancer patients, after one course of lymphocyte transfer immunotherapy, proved beneficial. Patient assessment of 14 cases after months of follow-up period revealed that nine showed improvement in the quality of life (Ohno et al. 2003). Nameda et al. (2003) tested the effect of SCG on white blood cells collected from human volunteers and observed that SCG dose-dependently enhanced IL-8 synthesis in both PMN (polymorphonuclear neutrophil) and PBMC (peripheral blood mononuclear cell) cultures. Therefore β-glucan can activate human leukocytes and related immune systems.

Harada et al. (2004) screened the cytokines induced by SCG, which includes granulocyte–macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor-α (TNF-α), IFN-γ, and interleukin-12 (IL-12p70). Hasegawa et al. (2004) examined the immunomodulatory effect of β-glucan fraction isolated from S. crispa, and reported that oral administration reduced the tumour size of sarcoma 180-bearing mice after 5 wk, as well as prolonged their survival. Oral administration of FHL (low molecular weight fraction) is also shown to induce antitumor activity by enhancing the Th1-response in tumour-bearing mice (Yamamoto et al. 2007). It also suppressed the tumour-induced angiogenesis in the dorsal air sac (DAS) system which may have contributed to the antitumor activity of FHL. β glucan activates dendritic cells via NF-κB signaling and Mitogen-Activated Protein Kinase (MAPK) pathways and thus helps in its maturation. Oral administration of the purified β-glucan extract (SBG) resulted in the suppression of tumour growth and metastasis in the lungs by inhibiting tumour-induced angiogenesis (Yamamoto et al. 2009). Kim et al. (2012) observed that β-glucan brings about phenotypic and functional maturation of dendritic cells, which are antigen-presenting cells of the immune system. Mycelia of S. crispa showed less tumour-suppressing activity.

### Table 2: Medicinal properties of different chemical constituents present in S. crispa

| Chemical constituents | Properties | Reference |
|-----------------------|------------|-----------|
| Indole, tryptamine, melatonin, gentisic acid, gallic acid, p-hydroxybenzoic acid, o-cumaric acid, caffeic acid, protocatechuic acid, syringic acid, and ergosterol | Antioxidant activity | Kawagishi et al. (2007) |
| Crude polysaccharides | used as a biocatalyst in the pharmaceutics, food, and chemical industries | Nowacka-Jechalke et al. (2021) |
| Alkaliphilic esterase | Anticancer activity | Chandrasekaran et al. (2011) |
| Crude polysaccharides | Anticancer activity | Harada et al. (2006) |
| 1,3-β-D glucan | used in cancer treatment | Ohno et al. (2000) |
| Polysaccharide fractions of 1,3 β-glucan | Antitumor activity | Ohno et al. (2000) |
| The β-glucan fraction CA1 | Antitumor activity | Ohno et al. (2002) |
| 3 novel phthalides- hanabiratakelide A (1), B (2), and C (3) | Antiallergic against rhinitis | Yoshikawa et al. (2010) |
| Sparasid A | Antiallergic against rhinitis | Wang et al. (2019) |
| β-glucan | wound healing capacity | Kimura et al. (2013) |
| Enhances increased production of adiponectin | Antidiabetic: regulates glucose levels and fatty acid breakdown | Yamamoto and Kimura (2010), |
| Xanthoangelol, 2 chalcones, and 4-hydroxyderricin | Anti-bacterial activity | Hayashi et al. (2008) |
| Sparassol and the other two were identified as incompletely determined methyl-dihydroxy-methoxy-methylbenzoate and methyl orsellinate | Anti-fungal activity (against Candida albicans) | Woodward et al. (1993) |
| Enhances NO production | Anti-hypertensive activity | Yoshitomi et al. (2011) |
compared with that of the basidiome. This difference in antitumor activity in between mycelia and basidiome of *S. crispa* might be attributed to the difference in structure and content of β-glucan (Kimura et al. 2013). Nowacka-Jechalke et al. (2021) carried out an in vitro study to evaluate the beneficial effects of crude polysaccharides from *S. crispa* against colon cancer. They observed that polysaccharides destroyed membrane integrity and inhibited the proliferation of human colon cancer cell lines: HT-29, LS180, and Caco-2. Therefore, it may be suggested that *S. crispa* contributes to reduction in the risk of various cancers. The stipe of *S. crispa* is also reported to exhibit immunomodulatory activity (Seo et al. 2016).

**Anti-inflammatory activity**

Allergic inflammatory diseases, such as asthma, allergic rhinitis (hay fever), food allergy, and atopic dermatitis, are quite prevalent across the globe. Some researchers have demonstrated anti-inflammatory activities in *S. crispa*. Hasegawa et al. (2004) reported that oral administration of *S. crispa* lowered the IgE level and scratching index of NC/Nga mice, which was induced by dermatitis (skin inflammation).

Anti-rhinitis activity of β-glucan is reported by many workers. Allergic rhinitis is a type of inflammatory condition which affects the nose due to overreaction of the immune system to air allergens. It is characterized by elevated production of IgE and mast cell degranulation, which results in histamine release. Yao et al. (2008) observed that oral administration of *S. crispa* (ultrafine powder from basidiomes) to mice had shown reduced symptoms of allergic rhinitis in a dose-dependent manner. Yoshikawa et al. (2010) isolated three novel phthalides—hanabiratak elide A (1), B (2), and C (3)—from the basidiomes of *S. crispa* which exhibited antiinflammatory activity. Kim et al. (2012) reported anti-inflammatory activity of water extracts of *S. crispa* (containing 39.6% β-glucan) on mast cell-mediated allergic inflammation in mice. Extracts play an inhibitory role in inflammatory reactions by regulating NO production (Sekiguchi 2005). Han et al. (2019) reported an anti-inflammatory effect of the non-aqueous fraction of an *S. crispa* methanol extract (SCF4) in lipopolysaccharide (LPS)-stimulated (RAW264.7) murine macrophage cells. Wang et al. (2019) reported the potential inhibitory effect of compounds from *S. crispa* on allergic rhinitis. Sparoside A was found to be the active anti-inflammatory compound with an IC50 value of 5.06 ± 0.60 µM.

**Anti-diabetic and wound healing activity**

Yamamoto and Kimura (2010), after feeding type 2 diabetic KK-Ay mice with an *S. crispa* diet for 3–6 wk, observed a significant increase in production of adiponectin, a protein hormone involved in regulating glucose levels and fatty acid breakdown in the plasma of diabetic mice. A substantial decrease in blood glucose and insulin levels was recorded after 3 wk administration of *S. crispa*, along with somewhat decreased levels of triglycerides and total cholesterol, which otherwise are elevated in diabetes. Yoshitomi et al. (2011) observed a preventive effect of *S. crispa* against hypertension and stroke in hypertensive rats. As the fungus alleviates dysfunctioning of the cerebrovascular endothelia by promoting recovery of Akt-dependent endothelial nitric oxide (eNOS) phosphorylation, it also increases NO production in the cerebral cortex.

The wound healing process is generally delayed or impaired in diabetic patients. β-glucan increases the macrophage infiltration and collagen biosynthesis and thus enhances wound healing capacity (Kimura et al. 2013). Neutrophils, keratinocytes, fibroblasts, endothelial cells, and macrophages are all important cells in wound repair, and pattern-recognition receptors for β-glucans have been identified on these cells (Lowe et al. 2002). β-glucans mediate their effects by activating leukocytes and stimulates their phagocytic activity. Dectin-1 is the major receptor for β-glucans on leukocytes (Choi et al. 2013).

Kwon et al. (2009) tested the wound healing property of *S. crispa* on STZ (streptozotocin) induced type 1 diabetic rats and observed that oral administration of *S. crispa* accelerated wound healing. This effect was linked to an increase in macrophage and fibroblast migration as compared to control. Moreover, the level of type I collagen was also higher in the treated group. Yamamoto and Kimura (2013) also reported that a diet supplemented with more than 0.5% *S. crispa* (ultra-fine powder from basidiomes) improved wound healing in diabetic mice. Topical administration of purified *S. crispa* β-glucan (SBG) also improved wound healing, resulting in a wound contraction ratio of 37% after 9 d of treatment.

Sharifi-Rad et al. (2020) also observed wound healing property in *S. crispa*. Oral administration of *S. crispa* (with a β-glucan content more than 40%) at a dose of 1 mg/kg b.w. per day for 4 wk, healed the wound through macrophage and fibroblast migration, increasing collagen regeneration, and wound epithelialization in STZ-induced diabetic rats.

**Antioxidant activity**

Oxidation is essential in many living organisms for energy production to fuel biological processes. However, uncontrolled production of oxygen leads to the release of free radicals which can induce many diseases, such as cancer, rheumatoid arthritis, and atherosclerosis, as well
as accelerating the aging process. Antioxidants present in dietary mushrooms can act as possible protective agents to help the human body reduce oxidative damage without any interference (Dhalaria et al. 2020). The phenolic compounds of mushrooms are known to have excellent antioxidant activity. Antioxidant activity of a compound can be assessed through a number of assays which include DPPH (2, 2-diphenyl-1-picrylhydrazyl) radical scavenging activity and oxidative-inhibitory capacity. Phenolic compounds and flavonoids are the major antioxidant compounds from S. crispa (Joshi & Sagar 2014). p-hydroxybenzoic acid, a phenolic derivative of benzoic acid, was found to be the quantitatively predominant antioxidant compound in S. crispa by Sułkowska-Ziaja et al. (2015). Crude polysaccharides from the mushroom are also reported as having antioxidant activity (Nowacka-Jechalke et al. 2021).

Puttaraju et al. (2006) analyzed the antioxidant activity of water and methanolic extracts of S. crispa basidiomes and other mushrooms for total anti-oxidative status, based on the inhibitory effect on lipid peroxidation, reducing power, and free radical scavenging activity. Moderate antioxidant activity was observed in water and methanolic extracts of S. crispa basidiomes. The phenolic content in S. crispa was observed as 5.5 mg/g (in water extract) and 1.7 mg/g (in methanolic extract). Kim et al. (2008) evaluated the antioxidant activity by DPPH scavenging activity and superoxide dismutase activity assay. Lee et al. (2016a, b, c) compared the antioxidant compounds and antioxidant activities of the S. crispa mycelium, based on extraction temperature (60 °C and 95 °C). That study revealed that the antioxidant activity of S. crispa extracted at 95 °C was better than that extracted at 60 °C, and the mycelium contained more antioxidant compounds in comparison to the pileus and stipe. Lee et al. (2016a, b, c) reported that S. crispa fermented with lactic acid bacteria (LAB) showed higher antioxidant activity. The activity was even higher when fermented with Meyerozyma guilliermondii (Park et al. 2016).

Anti-viral activity

Wang et al. (2007) investigated the effect of the hot water extracts of S. crispa, and 15 other mushroom species, on human immune deficiency virus (HIV)-1 reverse transcriptase (RT) activity. The extracts, at a concentration of 1 mg/ml, exhibited 70.3% inhibition.

Antibacterial activity

Hervey (1947) reported antibacterial activity of S. crispa against Staphylococcus aureus and Escherichia coli. S. crispa is also known to possess antimicrobial activity against many bacterial species including Bacillus mycoides, B. subtilis, B. pumilis, Comamonas terrigena, methicillin-resistant Staphylococcus aureus (MRSA), Micrococcus luteus, and Leuconostoc mesenteroides (Dyakov et al. 2011). Hayashi et al. (2008) isolated xanthoangelol, two chalcones, and 4-hydroxyderricin from extracts of S. crispa exhibiting anti-MRSA activity. Lee et al. (2013a) reported antimicrobial activity against some food poisoning bacteria, viz. B. cereus, Listeria monocytogenes, Salmonella typhimurium, and Staphylococcus aureus. The anti-microbial activity was maintained even after heating and treating with alcalase, indicating potential as a natural preservative in the food industry. Niazi and Ijaz (2021) evaluated the antibacterial potential of the ethanolic extract of S. crispa, which had a maximal effect against E. coli, with a potential inhibition zone (19.66±0.88 mm). Jang et al. (2015) observed growth inhibition of MRSA by S. crispa.

Anti-fungal activity

Woodward et al. (1993) isolated three antifungal metabolites from submerged cultures of S. crispa in 2% malt broth’ sparassol (methyl-2-hydroxy-4-methoxy-6-methylenzoate) was one of the compounds and the other two were identified as incompletely determined methyl-dihydroxymethoxy-methylbenzoate, and a methyl-2,4-di-hydroxy-6-methylbenzoate (methyl orsellinate). These compounds were also reported from the decayed wood of trees infected by S. crispa. Jang et al. (2015) observed growth inhibition of Candida albicans by S. crispa.

Antihypertensive activity

Hypertension, high blood pressure, is the most prevalent risk factor for stroke. Therefore, as a preventative measure for controlling a stroke one must control high blood pressure. The impact of S. crispa is well proved against Hypertension, high blood pressure, is the most prevalent risk factor for stroke. Therefore, as a preventative measure for controlling a stroke one must control high blood pressure. The impact of S. crispa is well proved against hypertension and stroke in stroke-prone spontaneously hypertensive rats (SHRSP) (Yoshitomi et al. 2011). The oral administration of 1.5% S. crispa to SHRSP from a young age delayed stroke and decreased blood pressure. The increased NO production acts as the main mechanism behind this, which improved the endothelial dysfunction with activation of the Akt/eNOS signaling pathway on the cerebral cortex.

Anti-obesity activity

Sparassis. crispa also prevents hepatic steatosis by lowering lipid content through activation of the beta-oxidation pathway. Experimentation was based on the detection of Lactobacillus-fermented S. crispa against obesity using a zebrafish model. The L-SC (lacto-fermented S. crispa) or orally administered S. crispa was subjected to diet-induced obese zebrafish for 4 weeks which resulted in suppression of body weight (20 μg/gBW/day).
significantly (P < 0.01) and ameliorated lipid accumulation in liver tissues (Matsuura et al. 2020).

CULTIVATION
Availability of S. crispa is scanty in nature, therefore artificial cultivation is practiced in many countries. At present, it is commercially cultivated in Japan, Korea, China, Germany, and the USA, mainly on sawdust of Larix trees. It can be cultivated by bottle, bag, and log cultivation methods using different solid and liquid media. The optimum temperature for mycelial growth is 20–25 °C, the optimum pH is slightly acidic (4–7), optimum atmospheric humidity 90–95% (Huang et al. 2007; Yu et al. 2010), and substrate moisture content of 65% (Yanquan et al. 2012) is considered best for its growth.

Shim et al. (1998) were probably the first to carry out studies to obtain basic information for the artificial culture of S. crispa. A pH of about 4 and a temperature around 25 °C was observed to be best for mycelial growth. Hamada media showed the most compact mycelia, while colony diameter was the largest in Hoppkins media. Park et al. (2006) reported that steam treatment of sawdust minimizes the cultivating period and increases the productivity of mushrooms. He used sawdust medium of Larix leptolepis, Pinus densiflora, and P. koreensis. Seo (2003) recorded an increase in thickness and growth of basidiomes by using light illumination (600–10,000 lx) in a culture medium comprised of conifer and broad-leaved tree sawdust in a ratio of 5:1 to 3:1 by weight. Lee et al. (2004) screened different sawdust media for suitability for mycelial growth. Six different kinds of sawdust were prepared, from oak (Quercus mongolica), mulberry (Morus alba), poplar (Populus deltoides), larch (Larix kaempferi), pine (Pinus densiflora), and Korean white pine (P. koreensis). Amongst these, sawdust made from Larix kaempferi was observed as giving the highest mycelial growth. Sekiguchi (2005) cultured S. crispa hyphae in an agar medium and prepared seed culture by using sawdust of conifers or mixed sawdust of conifers and deciduous trees. Farooq et al. (2014) reported that the application of electric pulse had a significant effect on basidiomes production and that the yield increased with increasing voltage of the electric pulse. Masuoka et al. (2015) reported that the amount of β-glucan in electric pulse-treated samples was 1.22 times higher than in control samples.

Oh et al. (2009) developed a simple method for mushroom cultivation on a conferous sawdust-based medium with molasses and wheat flour. They reported that cold shock for a day induced primordium formation. The sawdust medium of Pseudotsuga menziesii mixed with cottonseed meal, corn chip, wheat flour, and 10% molasses showed best productivity with 41%, followed by that of Larix leptolepis mixed with the same additives with 37% yield. Kurosumi et al. (2006) reported that mycelia raised by shaking liquid cultures shortens culturing time by about one third compared with conventional stationary liquid cultures. They suggested that this may be due to the more availability of dissolved oxygen and faster glucose consumption. At 30 g/L glucose concentration, pH 5 and temperature 25–30 °C, productivity of S. crispa mycelia reached its maximum.

Huang et al. (2007) used potato-dextrose-peptone agar (PDPA) medium for mycelial culture and pine sawdust with polished glutinous rice starch as a medium for basidiome production. The optimum temperature for mycelium growth and basidiome development was reported as 20–25 °C and 16–18 °C respectively, the optimum environment humidity as 90%-95%, and the optimum pH-value as 5–6. Yu et al. (2010) produced the mushroom using short logs of Larix leptolepis, Pinus densiflora, P. rigida, and Quercus acutissima. Mushroom production was highest on P. rigida logs. The optimal moisture content and temperature were 90 ~ 95% and 23–25 °C, respectively. Park et al. (2006) reported that the larch sawdust-based medium for the cultivation of S. crispa prepared as 0.76 g/cm³ in medium-density excluding particles less than 1 mm diam as best for mycelial growth. Jeong et al. (2011) reported that the optimal sugar content of media for mycelial growth was 6Bx with 25 °C as the optimum temperature and a pH of 5.0–6.0 for mycelial growth in liquid spawn, respectively. They used Larix kaempferi sawdust as the main material and observed that the mushroom yield, and cultivation period when supplemented with 20% corn flour and 10% wheat flour were highest and fastest, in terms of production respectively. Lu et al. (2011) investigated the effect of inorganic salts, vitamins, and phytohormones on the mycelial growth of S. crispa. Their result indicated that the growth rate of S. crispa reached its peak at concentrations of 1.0 g/L of magnesium sulfate, monopotassium phosphate, and sodium chloride. Among the vitamins, B1, B4 and B6 affected mycelial growth significantly; the best stimulatory vitamin for the growth was B4 at 8 mg/L. Among phytohormones, 6-BA and 6-KT stimulated the growth of S. crispa.

Yanquan et al. (2012) carried out a study to determine the optimum technological parameters for the cultivation of S. crispa. Their results indicated that 22 °C was the optimum temperature for mycelial growth with 65% as the optimal moisture content, and amount of substrate material in the range of 300–315 g/bag satisfies the nutritional requirements for industrial cultivation. Yan Quan et al. (2012) examined the growth rates of S. crispa mycelium on potato dextrose agar (PDA) media and reported the maximum growth rate in the range 22–24 °C. For culturing the mushrooms, they used a substrate of 76% sawdust, 18% wheat bran, 2%
cornmeal, 1.5% sucrose, 1.5% gypsum, and 1% calcium superphosphate. Mushroom yield was highest when the water content of the substrate was approximately 65% and the loading capacity was 900 g/bag. Ying et al. (2013) analysed the impact of exposure to light, varying in quality and quantity, on mycelial growth and primordium formation; they revealed that red light at 200 lx was most favourable for mycelial growth while yellow light was most conducive to primordium formation (Matsuura et al. 2020).

CONCLUSION AND FUTURE PROSPECTS

Sparassis crispa is an important wild edible and medicinal mushroom now cultivated in many countries. Besides high protein and vitamin content, it also contains a variety of physiologically active compounds which exhibit anti-tumour, anti-microbial, anti-oxidant, anti-inflammatory, and anti-hypertensive activities. The immunomodulating β-glucan from S. crispa plays a crucial role in modulating the immune response against cancer and has a stimulating effect on the innate immune system. It promotes wound healing in diabetic patients and shows anti-inflammatory activity via regulating the production of NO, implying that it could play a role in anti-inflammation therapy. The presence of phenolic compounds strengthens the antioxidant capacity. Extracts inhibit the growth of bacteria and fungi, indicating that the use of S. crispa in pharmaceuticals can protect humans from certain bacterial and fungal infections. The mushroom is considered edible all over the world, and no harmful effects have been recorded following human consumption. Polysaccharides of S. crispa also have potential for utilization in the food industries as a source of hydrocolloid (Choi et al. 2013). Therefore, using S. crispa as a dietary supplement may help in the treatment or be preventive of a variety of human diseases and ailments.

Acknowledgements

Authors are thankful to the Director and Vice-Chancellor of Himalayan Forest Research Institute, Shimla and Shoolini University respectively for the research encouragement and motivation.

Author contributions

Conceptualization, AT; formal analysis, AT, RV, DK; writing-original draft, NS; review writing, editing and interpretation, AT, RV, KK and EN and all authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.

Funding

The authors are grateful to Excelence project PrF UHK 2217/2022-2023 for the financial support.

Availability of data and material

Entire data has been added in the article itself.

Declarations

Ethics approval and consent to participate

No ethical issue involved.

Adherence to national and international regulations

Not applicable.

Consent for publication

Consent has been taken from all the authors.

Competing interests

All authors declare that they have no competing interest.

Author details

1 Himalayan Forest Research Institute, Conifer Campus, Panthaghati, Shimla 171013, India. 2 School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, Himachal Pradesh 173229, India. 3 School of Bioengineering and Food Technology, Shoolini University of Biotechnology and Management Sciences, Solan, Himachal Pradesh 173229, India. 4 Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech Republic.

Received: 12 June 2021   Accepted: 26 April 2022

Published online: 06 May 2022

References

Abasi F, Aminad M, Qureshi H. (2021) Historical evidence and documentation of remedial flora of Azad Jammu and Kashmir (AJK). In: Pharmacognosy-Medicinal Plants. InterchOpen. https://doi.org/10.5772/interchopen.96472

Andrew C, Diez J, James TY, Kauscerud H (2018) Fungarium specimens: a largely untapped source in global change biology and beyond. Philos Trans R Soc B 374(20170392). https://doi.org/10.1098/rstb.2017.0392

Aryal H, Budhathoki U (2013) Some wild mushrooms of Rupandehi district, West Nepal. Bibechna 10:34–43. https://doi.org/10.3126/bibechna.v10i05.9309

Bang R, Lee YJ (2019) A review on phytochemistry and pharmacology of Sparassis crispa. Korean J Herbal 34(6):131–138. https://doi.org/10.1016/j.jep.2019.02.041

Bang S, Lee C, Ryu J, Li W, Keh YS, Jeon JH, Lee J, Shim SH (2018) Simultaneous determination of the bioactive compounds from Sparassis crispa (Wulf) by HPLC-DAD and their inhibitory effects on LPS-stimulated cytokine production in bone marrow-derived dendritic cell. Arch Pharmacal Res 41(8):823–829. https://doi.org/10.1007/s12272-018-1054-y

Bashir KMI, Rhee KM, Kim MS, Cho MG (2020) The complete mitochondrial genome of an edible mushroom, Sparassis Crispa. Mitochondrial DNA B 5(1):862–869. https://doi.org/10.1080/23802359.2020.1715835

Burdzall HH, Miller DK (1988) Neotypification of Sparassis crispa Mycotaxon 31(2):591–593

Chandrasekaran G, Kim GJ, Shin HJ (2011) Purification and characterisation of an alkali-labile esterase from a culinary medicinal mushroom, Sparassis Crispa. Food Chem 124(4):1376–1381. https://doi.org/10.1016/j.foodchem.2010.07.094

Chauhan J, Negi AK, Rajasekaran A, Pala NA (2014) Wild edible macro-fungi- A source of supplementary food in Kinnaur District, Himachal Pradesh, India. J Med Plants Stud 2(1):40–44

Choi JH, Lee HJ, Kim S (2016) Purification and antithrombotic activity of wulfase, a fibrinolytic enzyme from the fruit bodies of the edible and medicinal mushroom Sparassis crispa Wulf. ex Fr. Appl Biochem Microbiol 52:608–614. https://doi.org/10.1134/S000368381606003X

Choi WS, Shin PG, Yoo YB, Noh H, Kim GD (2013) Anti-inflammatory activity of the blossom mushroom extract. Korean Mushroom Soc 37(2):105–120. https://doi.org/10.1111/j.1439-0329.2007.00485.x

Dai YC, Wang Z, Binder M, Hibbett DS (2006) Phylogenetics and a new species of Sparassis (Polyporales, Basidiomycota) evidence from mitochondrial genome of an edible mushroom, Sparassis Crispa. Mitochondrial DNA B 5(1):862–869. https://doi.org/10.1080/23802359.2020.1715835

Dai YC, Cui BK, Yuan HS, Li BD (2007) Pathogenic wood-decaying fungi in China. Forest Pathol 37(2):105–120. https://doi.org/10.1111/j.1439-0329.2007.00485.x
atp6, nuclear rDNA and rpb2 genes. Mycologia 98(4):584–592. https://doi.org/10.3852/mycologia.98.4.584
Devkota S (2009) The fleshy fungi, Sparassis crispa (Basidiomycetes: Polyporales) from Nepal. Sci World J 77:94–95. https://doi.org/10.1100/sw.v7i7.3835
Dhalia R, Verma R, Kumar D, Puris S, Tapawal A, Kumar V, Nepomovova E, Kuca K (2020) Bioactive compounds of edible fruits with their anti-aging properties: a comprehensive review to prolong human life. Antioxidants 9:112. https://doi.org/10.3390/antiox9111123
Dyakov MY, Kamzelinka OV, Shaer OA, Bisko NA, Poedinok NL, Mikhaliova OB, Tikonova OV, Tolstikhina TE, Vasileva BF, Efremenkovka OV. (2011) Morphological characteristics of natural strains of certain species of basidiomycetes and biological analysis of antimicrobial activity under submerged cultural conditions. Microbiology 80(2):274–285. https://doi.org/10.1134/S0021791811020044
Farooq MU, Chouza A, Ohga S (2014) Vegetative development of Sparassis crispa in various growth conditions and effect of electric pulse simulation on its fruit body production. Adv Microbiol 4(5):267–274. https://doi.org/10.4232/jam.2014.4.5.0303
Fries EM (1821). Systema Mycologicum, vol 1. Grifiswald: E. Mauritus
Farooq MU, Chioza A, Ohga S (2014) Vegetative development of Sparassis crispa for cosmetic ingredients. J Korean Oil Chem Soc 32:731–739. https://doi.org/10.12925/jkocs.2015.32.4.731
Jeong JS, Yoon YJ, Seo SY, Yu YB (2011) Selection of suitable conditions of mycelial growth and materials of bag cultivation in Sparassis crispa. J Mushrooms 9(2):80–83
Joshi M, Sagar A (2014) In vitro free radical scavenging activity of a wild edible mushroom, Sparassis crispa (Wulf.) Fr., from North Western Himalayas India. J Mycol. https://doi.org/10.1155/2014/748531
Jülich W (1984) Basidiomycetes of SouthEast Asia. Int J Mycol Lichenol
Kalyoncu F, Ergönül B, Yildiz H, Kalmij H, Solak H (2010) Chemical composition of four wild edible mushroom species collected from Southwest Anatolia. Gazi Univ J Sci 23(4):375–379
Kamble VR, Mane SK, Khilare CJ (2012) Host specificity of some wood rotting fungi in Western Ghats of Maharashtra, India. Bionano Front 5(2):217–223
Karadžić D (2006) Contribution to the study of the fungi in the genera Sparassis Fr. and Hemicium Pers. in our forests. Glasnik Sumarskog Fakulteta 93:83–96. https://doi.org/10.2298/GSF0693083K
Kavishree S, Hemavathy J, Lokesh BR, Shashikshna MN, Rajarathnam S (2008) Fat and fatty acids of Indian edible mushrooms. Food Chem 106(2):597–602. https://doi.org/10.1016/j.foodchem.2007.06.018
Kawagishi H, Hayashi K, Tomiyama S, Hashimoto N, Kimura T, Dombro M (2007) Novel bioactive compound from the Sparassis crispa mushroom. Biosci Biotechnol Biochem 71(7):1804–1806. https://doi.org/10.1271/bbb.710912
Kim HHS, Singh TSK, Choi JK, Shin TY, Kim SH (2012) Sparassis crispa suppresses mast cell-mediated allergic inflammation: Role of calcium, mitogen-activated protein kinase and nuclear factor-κB. Intl J Mol Med 30(2):344–350. https://doi.org/10.3892/ijmm.2012.1000
Kim HS, Kim JY, Ryu HS, Park HG, Kim YO, Kang JS, Kim HM, Hong JT, Kim Y, Han SB (2010) Induction of dendritic cell maturation by β-glucan isolated from Sparassis crispa. Int Immunopharmacol 10(10):1284–1294. https://doi.org/10.1016/j.intimp.2010.07.012
Kim MY, Seguin P, Ahn JK, Kim JJ, Chun SC, Kim EH, Seo SH, Kang EY, Kim SL, Park YJ, Ro HM, Chung IM (2008) Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea. J Agric Food Chem 56(17):7265–7270. https://doi.org/10.1021/jf8008533
Kimura T, Yamamoto K, Nishikawa Y (2013) Selection of suitable conditions of mycelial growth and materials of bag cultivation in Sparassis crispa. J Food Prop 21(1):2283–2295. https://doi.org/10.1080/104922112.2013.1581088
Harada T, Kawaminami H, Miura NN, Adachi Y, Nakajima M, Yadoade M, Ohno N (2006) Mechanism of enhanced hematopoietic response by soluble β-glucan in cyclophosphamide-treated mice. Microbiol Immunol 50(6):697–700. https://doi.org/10.1111/j.1348-0421.2006.tb08341.x
Harada T, Miura NN, Adachi Y, Nakajima M, Yadoade M, Ohno N (2002a) Effect of Scg, 1,3-beta-D-glucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice. Biol Pharm Bull 25(7):931–939. https://doi.org/10.1248/bpb.25.931
Harada T, Miura NN, Adachi Y, Nakajima M, Yadoade M, Ohno N (2002b) Induction by SCG, 1,3-B-D-Glucan from Sparassis crispa, in DBA/2 mice in vitro. J Interferon Cytokine Res 22(12):1227–1229. https://doi.org/10.1081/JIR-100000264
Harada T, Miura NN, Adachi Y, Nakajima M, Yadoade M, Ohno N (2004) Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates cytokine induction by 1,3-β-D-glucan Scg in dba/2 mice in vitro. J Interferon Cytokine Res 24(7):478–489. https://doi.org/10.1089/10799009.2004.9004168956
Hasegawa A, Yamada M, Dombro M, Fukushima K, Matsuura N, Sugitachi A (2004) Sparassis crispa as biological response modifier. Cancer Chemother Pharmacol 53(1):1761–1763
Hayashi K, Tomiyama S, Hashimoto M, Kimura T, Dombro M, Kawagishi H (2008) Occurrence and identification of chalcones from the culinary-medicinal cauliflower mushroom Sparassis crispa (Wulf) Fr. (Aphyllophoromycetidae). J Med Mushrooms. 10(4):331–336. https://doi.org/10.1615/JIntMedMushr.v10.i4.50
Hervey AH (1947) A survey of 500 basidiomycetes for antibacterial activity. Bull Torrey Bot Club 74(6):476–503
Horie K, Rakwal R, Hirano M, Shibato J, Nam HW, Kim YS, Yonekura M (2008) Proteomics of two cultivated mushrooms Sparassis crispa and Hemicium erinaceum provides insight into their numerous functional protein components and diversity. J Proteome Res 7(5):1819–1835. https://doi.org/10.1021/pr070369c
Huang JC, Chi ZX, Wang MZ, Yu YR, Ying ZH (2007) Study on domestication cultivation of Sparassis crispa (Wulf.) Fries. Acta Agriculturae Jiangxi. 18(10):120–122
Yang Y, Kim HR, Yang JG, Lee JW, Kim BA, Lee JT (2015) A study on the possibility of extracts from Sparassis crispa for cosmetic ingredients. J. Korean Oil Chem Soc 32:731–739. https://doi.org/10.12925/jkocs.2015.32.4.731
Lee DS, Kim KH, Yook HS (2016a) Antioxidant activities of different parts of Sparassis crispa depending on extraction temperature. J Korean Soc Food Nutr Sci 45:1617–1622. https://doi.org/10.3746/jkfsn.2016.45.11.1617
Lee EJ, Kim JE, Park MJ, Park DC, Lee SP (2013) Antimicrobial effect of the submerged culture of Sparassis crispa in soybean curd whey. Korean J Food Preserv 21(1):111–120. https://doi.org/10.11002/kjfp.2013.20.1.111
Lee JJ, Son HY, Choi YM, Cho JH, Min JK, Oh HK (2016b) Physicochemical components and antioxidant activity of Sparassis crispa mushroom fermented by lactic acid bacteria. Korean J Food Preserv 23(3):361–368. https://doi.org/10.9721/KJFST.2020.52.4.377
Lee JM, Kim JY, Choi KD, Han KD, Hur H, Kim SW, Shim JQ, Lee JY, Lee TS, Lee MW (2004) Sawdust media affecting the mycelial growth and the fruiting body formation of Sparassis crispa. Mycobiology 32(4):190–193
Lee YG, Lee NH, Lee DY, Lee SE, Kim GS, Baek NL (2016c) Ergosterol peroxides from the fruit body of Sparassis crispa. J Abpil Biol Chem 59(4):313–316. https://doi.org/10.3898/jabc.2016.503
Lowe EP, Wei D, Rice PJ, Li C, Kalbfleisch J, Browder IW, Williams DL (2002) Immunopharmacological characterization of the Mycorrhizal fungus, SC-G, extracted from a medicinal mushroom, Sparassis crispa Wulf.: Fr. (Aphyllophoromycetideae), and application to preparation, SCG, extracted from a culinary and medicinal mushroom, Sparassis radicata (Wulf. in Polyporus schweinitzii). Int J Med Mushrooms 4(1):14. https://doi.org/10.1615/IntJM edMus hr. v4. i1. 20
Matsuura N, Zang L, Nakamura Y, Teranishi K, Park HG, Shim YY, Choi SO, Park WM (2009) New method development for nanoparticle extraction of water-soluble β-1,3-D-glucan from edible mushrooms, Sparassis crispa and Phellinus linteus. J Agric Food Chem 57(6):2147–2154. https://doi.org/10.1021/jf902940x
Matsushita N, Kanasugi K, Miyazawa R, Tegawi J, Akioka Y, Kato K, Matsuda M (2013) Characterization of the habitat of cauliflower mushroom (Sparassis crispa (Wulf. in Polyporus schweinitzii) Von-Siepmann R (1976) Fungorum qui Bavaria et palatinate circa Ratisbonam descripsit. Schaeffer JC (1772) Fungorum qui Bavaria et palatinate circa Ratisbonam descripsit. Schizophrum commune (Fr.) Fr. and Sparassis crispa (Wulf.: Fr.) Fr. Economic Significance and Medicinal Properties. Udruženje Sarmskih Inženjera i Tehničara Srbije, Beograd (Srbija) 171(2)–19–36. https://doi.org/10.1089/jmf.2019.4571
Miyashita, Tada R, Harada T, Nagi-Miura N, Adachi Y, Nakajima M, Yadomae T, Ohno N, (2016) Antioxidant activity and hematopoietic response of β-Glucan preparation, SCG, extracted from a medicinal mushroom, Sparassis crispa (Wulf.: Fr.). J Microbiol 51(1):43–48. https://doi.org/10.1089/jmf.2019.4571
Miyazawa T, Kawakami T, Kyoshima T, Asada C, Nakamura Y, Teranishi K, Shimomura N (2015) Effect of pulsed discharges on mycelial growth and the fruiting body formation of Sparassis radicata and related species. Mycologia 68(3):622–639. https://doi.org/10.1002/myc.201419947
Miyazaki T, Kadota T, Harada T, Nagi-Miura N, Adachi Y, Nakajima M, Ohno N, (2005) Antitumor activity and hematopoietic response of β-Glucan preparation, SCG, extracted from a medicinal mushroom, Sparassis crispa (Wulf.: Fr.). Immunopharmacol Immunotoxicol 27(3):321–335. https://doi.org/10.1081/IPH-200042500
Nasim G, Bajwa R, Ali M (2007) Sparassis crispa (Wulf.) Fr., the cauliflower fungus (Aphyllophoromycetideae), and application to preparation, SCG, extracted from a medicinal mushroom, Sparassis radicata (Wulf. in Polyporus schweinitzii). Int J Med Mushrooms 4(1):14. https://doi.org/10.1615/IntJM edMus hr. v4. i1. 20
Nasim G, Bajwa R, Ali M (2007) Sparassis crispa (Wulf.) Fr., the cauliflower fungus (Aphyllophoromycetideae), and application to preparation, SCG, extracted from a medicinal mushroom, Sparassis radicata (Wulf. in Polyporus schweinitzii). Int J Med Mushrooms 4(1):14. https://doi.org/10.1615/IntJM edMus hr. v4. i1. 20
Namaeda S, Harada T, Miura NN, Adachi Y, Yadomae T, Nakajima M, Ohno N (2003) Enhanced cytokine synthesis of leukocytes by a β-glucan preparation, SC-G, extracted from a medicinal mushroom, Sparassis crispa Wulf.: Fr. (Aphyllophoromycetideae). Int J Med Mushrooms 4(1):14. https://doi.org/10.1615/IntJM edMus hr. v4. i1. 20
Wang J, Wang HK, Ng TB (2007) A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa. Peptides 28(3):560–565. https://doi.org/10.1016/j.peptides.2006.10.004
Wang Z, Binder M, Dai YC, Hibbett DS (2004) Phylogenetic relationships of Sparassis inferred from nuclear and mitochondrial ribosomal DNA and RNA polymerase sequences. Mycologia 96(5):1015
Wang Z, Liu J, Zhong X, Li J, Wang X, Ji L, Shang X (2019) Rapid characterization of chemical components in edible Mushroom Sparassis crispa by UPLC-orbitrap MS analysis and potential inhibitory effects on allergic rhinitis. Molecules 24(16):3014. https://doi.org/10.3390/molecules24163014
Woods S, Sultan HY, Barrett DK, Pearce RB (1993) Two new antifungal metabolites produced by Sparassis crispa in culture and in decayed trees. J Gen Microbiol 139(1):153–159. https://doi.org/10.1099/0022287-139-1-153
Wulffen FX (1781) Plantae raiores carinthiacae. In: Jacquin, NJ, Miscellanea Austriacae, vol 2. Officina Krausiana, Vienna
Yamamoto K, Kimura T (2010) Dietary Sparassis crispa (Hanabiratake) ameliorates plasma levels of adiponectin and glucose in Type 2 diabetic mice. J Health Sci 56:541–546. https://doi.org/10.1248/jhs.56.541
Yamamoto K, Kimura T (2013) Orally and topically administered Sparassis crispa (Hanabiratake) improved healing of skin wounds in mice with streptozotocin-induced diabetes. Biosci Biotechnol Biochem 77(6):1303–1305. https://doi.org/10.1271/bbb.121016
Yamamoto K, Kimura T, Sugitachi A, Matsuura N (2009) Anti-angiogenic and anti-metastatic effects of β-1,3-D-glucan purified from Hanabiratake, Sparassis Crispa. Bio Pharm Bull 32(2):259–263. https://doi.org/10.1248/bpb.32.259
Yamamoto K, Unitika L, Nishikawa Y, Kimura T, Dombo M, Matsuura N, Sugitachi A (2007) Antitumor activities of low molecular weight fraction derived from the cultured fruit body of Sparassis crispa in tumor-bearing mice. J Jpn Soc Food Sci Technol (Japan) 54(9):419–423
YanQuan L, Lu M, XiaoLing J, ZhengHe Y (2012) Optimization of selected growth parameters for Sparassis crispa. Acta Edulis Fungi 19(4):35–37
Yao M, Yamamoto K, Kimura T, Dombo M (2008) Effects of Hanabiratake (Sparassis crispa) on allergic rhinitis in OVA-sensitized mice. Food Sci Technol Res 14:589–594. https://doi.org/10.3136/fstr.14.589
Ying ZH, Lin YQ, Ma L, Jiang XL (2013) Effects of different light quality and quantity on mycelial growth and primordium formation of Sparassis crispa: Fujian J Agric Sci 6:005 ((in Chinese))
Yoshikawa K, Kokudo N, Hashimoto T, Yamamoto K, Inose T, Kimura T (2010) Novel phenylheide compounds from Sparassis crispa (Hanabiratake), Hanabiratakide A–C, exhibiting anti-cancer related activity. Bio Pharm Bull 33(8):1355–1359. https://doi.org/10.1248/bpb.33.1355
Yoshimoto H, Iwaoka E, Kubo M, Shibata M, Gao M (2011) Beneficial effect of Sparassis crispa on stroke through activation of Akt/eNOS pathway in brain of SHRSP. J Nat Med 65(1):135–141. https://doi.org/10.1007/s11418-010-0475-9
Yu YJ, Seo SY, Seo KW, Choi DC, Jo HK, Yu YB, Soung YJ, Ryu J (2010) Technical development for the short-log bag cultivation of Sparassis crispa. J Mushrooms 8(1):16–21
Zhao Q, Feng B, Yang ZL, Dai YC, Wang Z, Tolgor B (2013) New species and distinctive geographical divergences of the genus Sparassis (Basidiomycota): Evidence from morphological and molecular data. Mycol Prog 12(2):445–454. https://doi.org/10.1007/s11557-012-0853-7

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.